Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

European Society of Cardiology

The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. European Heart Journal, 21, 1216-1231. [Pg.85]

Current European Society of Cardiology (ESC) guidelines recommend ACE-inhibitor therapy in CAD patients with co-existing indications for ACE-inhibitors, such as hypertension, heart failure, left ventricular dysfunction, prior MI with left ventricular dysfunction, or diabetes (class I, level of evidence A). These guidelines also recommend ACE-inhibitor therapy in all patients with angina and proven coronary disease (class Ila, level of evidence B). [Pg.588]

Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991 84 1831-51. [Pg.606]

Alpert JS, Thygesen k, Antman E, et al. Myocardial infarction redefined, A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, J Am Coll Cardiol 2000 36 959-969. [Pg.56]

Montalescot G and the STEEPLE investigators. The STEEPLE study safety and efficacy of intravenous enoxaparin in elective percutaneous coronary inten/ention an international randomized evaluation. European Society of Cardiology 2005 Hotline session. [Pg.84]

Bertrand ME, Simoons ML, Fox KA, et al, Task force on the management of acute coronary syndromes of the European Society of Cardiology, Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J 2002 23 1 809-1 840. [Pg.124]

Patrono C, Bachmann E Baigent C, et al. European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004 25 166-181. [Pg.151]

Newby AC, Biological/pharmacological treatment and prevention, XXIInd Congress of the European Society of Cardiology, Amsterdam, Netherlands, Aug 27-30, 2000,... [Pg.261]

BartunekJ, Dimmeler S, Drexler H, et al. The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. Eur HeartJ 2006 27 1338-1340. [Pg.436]

Silber S, Albertsson R Aviles FR et al. Task force for percutaneous coronary interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005 26(8) 804—847. [Pg.534]

Apple FS, Quist HE, Doyle PJ, et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 49 1331-1336,2003. [Pg.65]

Apple FS, Wu AHB, Jaffe AS European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction how to use existing assays clinically and for clinical trials. Am Heart J 144 981-986, 2002. [Pg.65]

The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur. Heart]., 2004, 25, 1454-1470. [Pg.179]

Haverkamp, W., Breithardt, G., Camm, A.J., Janse, M.J., Rosen, M.R., Antzelevitch, C., Escande, D., Franz, M., Malik, M., Moss, A., Shah, R. (2000). The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur. Heart J. 21 1216-31. [Pg.505]

Ryden L, Standi E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases executive summary the task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2007 28 88-136. [Pg.1028]

European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guide-hues for the management of arterial hypertension. J Hypertens 2003 21(6) 1011-53. [Pg.262]

See other pages where European Society of Cardiology is mentioned: [Pg.102]    [Pg.16]    [Pg.117]    [Pg.131]    [Pg.131]    [Pg.79]    [Pg.600]    [Pg.607]    [Pg.2]    [Pg.5]    [Pg.9]    [Pg.93]    [Pg.141]    [Pg.490]    [Pg.601]    [Pg.611]    [Pg.104]    [Pg.55]    [Pg.80]    [Pg.102]    [Pg.496]    [Pg.232]    [Pg.273]    [Pg.273]    [Pg.790]    [Pg.790]    [Pg.1643]   
See also in sourсe #XX -- [ Pg.474 ]



SEARCH



Cardiology

European Society of Cardiology (ESC

© 2024 chempedia.info